Hoping to Clone Some Profits

After a slow start, bioengineering products head for the market

Since its founding nearly a decade ago, the biotechnology industry has become expert at cloning genes, but it has not cloned many profits. Despite investments in research and development that have exceeded $2 billion, only a handful of marketable products have emerged from the laboratory. But 1984 may be the year when biotechnology begins to live up to its vaunted potential. A number of new products are working their way through the arduous testing process. Some of the most promising substances that researchers hope...

Want the full story?

Subscribe Now


Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!